The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
Cotellic [package insert].South San Francisco, CA: Genentech Inc., 2015.
2.
HoeflichK.P.MerchantM.OrrC.Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res.2012; 72(1): 210–219.
3.
HanK.JinJ.Y.MarchandM.Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemother Pharmacol.2015; 76(5): 917–924.
4.
LarkinJ.AsciertoP.A.DrénoB.Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med.2014; 371(20): 1867–1876.
5.
ShapiroG.LoRussoP.KwakE.L.Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors [abstract 3005]. J Clin Oncol.2011; 29(suppl).
ChangT.C.ShiahH.S.YangC.H.Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol.2015; 75(3): 579–586.
KoA.H.TemperoM.A.ShanY.S.A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer.2013; 109(4): 920–925.
10.
RoyA.C.ParkS.R.CunninghamD.A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastrooesophageal junction adenocarcinoma. Ann Oncol.2013; 24(6): 1567–1573.
11.
Von HoffD.LiC.P.Wang-GillamA.NAPOLI-1: Randomized phase 3 study of MM-398 (Nal-Iri), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy [abstract]. Ann Oncol.2014; 25(suppl 2): ii105–ii106. http://annonc.oxfordjournals.org/content/25/suppl_2/ii105.4.full. Accessed November 24, 2015.
